Menu
Not yet recruiting NCT07682181

Efficacy of Facial Massager in Reducing Intra Oral Injection Pain in Pediatric Patients

No phase Interventional Local Anesthesia Infiltration

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Facial T massager, Topical Benzocaine 20%.
Who it may be relevant to
Registry conditions: Local Anesthesia Infiltration. Basic parameters: 4 years — 12 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy of a Vibrating Facial-T- Massager as an Adjunct to Topical Anesthesia in Reducing Intraoral Injection Pain in Children: A Randomized Controlled Trial.

Overview

Abstract * Background: Local anesthesia is a primary source of anxiety in pediatric dentistry. * Objective: To evaluate if mechanical vibration from a low-cost facial massager reduces pain and anxiety during injections using the Gate Control Theory. * Design: Prospective Randomized Controlled Trial .

Detailed description

Methodology \& Study Design

* Setting: Pediatric Dental Department, Kadapa, Andhra Pradesh. * Inclusion Criteria: Children aged 4-12 years requiring local anesthesia, cooperative (frankl 3,4) * Exclusion Criteria: History of allergy to benzocaine, acute infection at the site, or special healthcare needs affecting sensory perception, Medically compromised, unco-operative children, those who do not consent.

Intervention Protocol

1. Group 1: Application of 20% Benzocaine gel for 2 minutes followed by a standard local anesthetic injection. 2. Group 2: Application of Facial Massager on the buccal mucosa 30 seconds prior to and during the injection. 3. Group 3: Application of 20% Benzocaine gel for 2 minutes + Facial Massager applied to the buccal mucosa 30 seconds prior to and during the injection. 4. Infection Control \& Sterilization

To ensure patient safety, the following protocol for the non-medical T-massager will be implemented:

* Barrier Protection: The device will be encased in a single-use, disposable polyethylene sleeve (Digital Sensor Sleeve) and secured with tape. * Disinfection: After barrier removal, a "Double-Wipe" method using 70% Isopropyl Alcohol wipe will be used.

Interventions

  • Device Facial T massager
    vibrating facial T massager used to apply on mucosa for mechanical stimulation and gate control
  • Drug Topical Benzocaine 20%
    topical application of mucopain gel for 30 seconds

Primary outcome measures

  • self reort of pain [Time frame: after injection]
Secondary outcome measures (1)
  • physiologic parameter [Time frame: pre and during administration of local anesthesia]

Eligibility criteria

Inclusion criteria

  • Children aged 4-12 years requiring local anesthesia
  • Cooperative behaviour (frankl rating 3,4)

Exclusion criteria

  • History of allergy to benzocaine
  • acute infection at the site
  • special healthcare needs affecting sensory perception
  • Medically compromised children
  • unco-operative children
  • those who do not consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Hambouta HM, Sharaf DA, Wahba NA. Effectiveness of cold vibratory stimuli on pain perception governing infiltration anesthesia in the maxillary arch in children: a randomized controlled clinical trial. BMC Oral Health. 2025 Jun 3;25(1):900. doi: 10.1186/s12903-025-06170-4. PMID 40462040

Identifiers

NCT: NCT07682181 · pr.69/IEC/GDCH/KDP/2025-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗